In late January, we had the pleasure of covering the inaugural Longevity Therapeutics symposium in San Francisco. The event, sponsored by global conference organizer Hanson Wade, sought to bring together the leading biotech drug developers, academics, investors and pharma companies currently engaged in creating innovative therapies targeting age-related conditions.
The sessions focused on specific challenges that we face as we work toward these therapies, including discovery, preclinical activities, translational research, clinical development, and regulatory and commercial considerations, and provided a wealth of details about the most recent developments in this space.
While hearing the talks and meeting the other attendees, I was again struck by a trend that I first noted at the Bay Area Aging Meeting in late 2018, when I realized that many of the participants were from longevity-related startups. This would simply not have been true as recently as 5 years ago.
It is clear that the field is undergoing a radical shift from a primarily academic enterprise to one in which there is an active exchange between fundamental researchers and the increasing number of for-profit enterprises working to translate basic findings into medications and therapies. Far more than half of the 200 or so registrants at Longevity Therapeutics were from companies. Some of those people entered the commercial field from universities and continue to keep their foot in the door of academia, maintaining research labs while also devoting effort to enterprises.
The two-day conference was extremely informationally dense, so we’ve broken up our comprehensive coverage in a series of articles:
We hope that you enjoy reviewing our summaries of the talks and discussions of the conference. Hanson Wade’s representatives informed me that this will be an annual event, and we’re already looking forward to next year.